The Acute Care™ CK-MB assay is an in vitro diagnostic test for the measurement of the MB iso-enzyme of creatine kinase in heparinized whole blood/plasma. CK-MB measurements can be used as an aid in diagnosing acute myocardial infarction.
Features & Benefits
- One sample, one run, one instrument; increases efficiency in triaging chest pain patients
- Rapid turnaround time - in as little as 14 minutes (with onboard centrifugation)
- Single and ready to use TestPak™ Cartridges
o No reconstitution
o No warming to room temperature
o Reduction in reagent waste
o Reduction in contamination
- Heparinized whole blood samples
- Electronic QC (System Check) satisfies daily routine QC requirements permitting liquid QC flexibility
CK-MB is found primarily in cardiac tissue.1 CK-MB can be detected at elevated concentrations following myocardial damage. Abnormal plasma CK-MB concentrations are often associated with ischemia or necrotic heart injury. The increase in CK-MB concentration is often evident within 3 to 6 hours following onset of chest pain, reaching peak concentrations within 12 to 24 hours. CK-MB concentrations will generally return to normal within 24 to 72 hours.2 The determination of CK-MB is most beneficial when samples have been drawn at appropriate time intervals post onset of chest pain.
1 Lang H, ed. Creatine kinase isoenzymes: pathophysiology and clinical application. Berlin: Springer-Verlag, 1981.
2 Roberts R. Heart Lung 1981;10(3): 486-506
The products/features (mentioned herein) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.